Enroll in NUCYNTA® ER/NUCYNTA® Pain Pulse

Designed to offer helpful resources and tools for your practice!

Sign up for the NUCYNTA® ER/NUCYNTA® Pain Pulse Program below to join a community of healthcare providers like yourself. As part of this community, you'll receive e-mail communications on pain management, helpful tools for your practice, and information on upcoming interactive videoconferences. Don't miss out on Pain Pulse!

    *Required field

    *
    *
    *
    *
    *
    *
    *
    *
    *

    Please enter one of the following:

    or
    *



    By providing your information, you are requesting to receive future NUCYNTA® ER and NUCYNTA® branded and unbranded communications and resources from Janssen Pharmaceuticals, Inc., where your information will be used only to satisfy this purpose. Your information will be shared by Janssen Pharmaceuticals, Inc., with their affiliates and third parties involved in fulfilling your information request. You can request to remove your participation at any time by clicking here. All information you provide will be governed by our Privacy Policy. By providing us your information and selecting SUBMIT, you attest that you have read, understand, and agree to these conditions.

     

    NUCYNTA® ER is an opioid agonist indicated for the management of:

    • • Moderate to severe chronic pain in adults.

    • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults.

    When a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

    NUCYNTA® ER is not intended for: • Use as an as-needed (prn) analgesic. • For pain that is mild or not expected to persist for an extended period of time. • For acute pain. • For postoperative pain unless the patient is already receiving chronic opioid therapy prior to surgery, or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time.

    NUCYNTA® ER IMPORTANT SAFETY INFORMATION

    WARNING: ABUSE POTENTIAL, LIFE-THREATENING RESPIRATORY DEPRESSION, ACCIDENTAL EXPOSURE, and INTERACTION WITH ALCOHOL

    Abuse Potential

    NUCYNTA® ER contains tapentadol, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit. Assess each patient’s risk for opioid abuse or addiction prior to prescribing NUCYNTA® ER. The risk for opioid abuse is increased in patients with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depressive disorder). Routinely monitor all patients receiving NUCYNTA® ER for signs of misuse, abuse, and addiction during treatment.

    Life-threatening Respiratory Depression

    Respiratory depression, including fatal cases, may occur with use of NUCYNTA® ER, even when the drug has been used as recommended and not misused or abused. Proper dosing and titration are essential, and NUCYNTA® ER should only be prescribed by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain. Monitor for respiratory depression, especially during initiation of NUCYNTA® ER or following a dose increase. Instruct patients to swallow NUCYNTA® ER tablets whole. Crushing, dissolving, or chewing NUCYNTA® ER can cause rapid release and absorption of a potentially fatal dose of tapentadol.

    Accidental Exposure

    Accidental ingestion of NUCYNTA® ER, especially in children, can result in a fatal overdose of tapentadol.

    Interaction With Alcohol

    The co-ingestion of alcohol with NUCYNTA® ER may result in an increase of plasma levels and potentially fatal overdose of tapentadol. Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while on NUCYNTA® ER.

    • After abrupt discontinuation or a significant dose reduction of NUCYNTA® ER in physically dependent patients. When discontinuing NUCYNTA® ER, gradually taper the dose.
    • If mixed agonists/antagonists (e.g., butorphanol, nalbuphine, pentazocine) and partial agonists (e.g., buprenorphine) are used in patients who have received or are receiving NUCYNTA® ER. Avoid the use of mixed agonists/antagonists and partial agonists with NUCYNTA® ER.
    • If opioid antagonists (e.g., naloxone, nalmefene) are administered in physically dependent patients. Administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.
    • Renal: Use of NUCYNTA® ER in patients with severe renal impairment (CLCR <30 mL/min) is not recommended due to accumulation of a metabolite formed by glucuronidation of tapentadol. The clinical relevance of the elevated metabolite is not known.
    • Hepatic: Avoid use of NUCYNTA® ER in patients with severe hepatic impairment (Child-Pugh Score 10-15); reduce the dose in patients with moderate impairment (Child-Pugh Score 7-9); and monitor for respiratory and CNS depression when initiating and titrating NUCYNTA® ER.

     

    NUCYNTA® (tapentadol) is indicated for the management of moderate to severe acute pain in adults.

    NUCYNTA® IMPORTANT SAFETY INFORMATION

    Contraindications: Significant respiratory depression; acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to tapentadol or to any other ingredients of the product; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days.

    • After abrupt discontinuation or a significant dose reduction of NUCYNTA® in physically dependent patients. When discontinuing NUCYNTA®, gradually taper the dose.
    • If mixed agonists/antagonists (e.g., butorphanol, nalbuphine, pentazocine) and partial agonists (e.g., buprenorphine) are used in patients who have received or are receiving NUCYNTA®. Avoid the use of mixed agonists/antagonists and partial agonists with NUCYNTA®.
    • If opioid antagonists (e.g., naloxone, nalmefene) are administered in physically dependent patients. Administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.
    • Renal: Use of NUCYNTA® in patients with severe renal impairment (CLCR <30 mL/min) is not recommended due to accumulation of a metabolite formed by glucuronidation of tapentadol. The clinical relevance of the elevated metabolite is not known.
    • Hepatic: Avoid use of NUCYNTA® in patients with severe hepatic impairment (Child-Pugh Score 10-15); reduce the dose in patients with moderate impairment (Child-Pugh Score 7-9).

    Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients in the lower range of recommended doses.

     

    002331-130909